Tissue Clearance of Rofenaid® in Chickens and Turkeys

Fellig, J.; Westheimer, Joseph; Walsh, Mary J.; Marusich, W. L.

doi:10.3382/ps.0501777

Cited by 12 publications

(12 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results from the prophylactic level are in agreement with Fellig et al (1971), who noted levels of .9 to 1.3 ppm after 13 days of feeding SDM at .00625%. The results from the therapeutic treatment support the idea of fast absorption of sulfa drugs and are in agreement with the results of Atef et al (1978), who noted highest plasma levels of sulfamerazine after 6 hr of administration at 200 and 500 mg/kg of body weight.…”

Section: Resultssupporting

confidence: 89%

“…Most of the studies conducted with SDM deal with its depletion from tissue and blood. Fellig et al (1971) found SDM levels from .9 to 1.3 ppm at 0 day withdrawal when SDM was 1 Oregon Extension Technical Publication No.2 2 This project was supported by the United States Department of Agriculture, Extension Service Grant Number 12-05-300-596. Fellig et al (1971) found SDM levels from .9 to 1.3 ppm at 0 day withdrawal when SDM was 1 Oregon Extension Technical Publication No.2 2 This project was supported by the United States Department of Agriculture, Extension Service Grant Number 12-05-300-596.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Accumulation Rate in the Whole Blood of Market Turkeys Fed Prophylactic and Therapeutic Levels of Sulfadimethoxine

et al. 1986

View full text Add to dashboard Cite

A study was conducted to determine the accumulation of sulfadimethoxine (SDM) in the blood of market turkeys. Fifty-two 12-week-old female turkeys were fed SDM at either prophylactic or therapeutic levels, .00625 and .03125% (w/w), respectively, for 24 days. A semiqualitative test, the Whole Blood Sulfa Test (WBST), was used to determine sulfa levels in the whole blood. Blood samples were obtained at 0, 3, 6, 12, and 24 hr for the first day for both groups after the incorporation of SDM in the feed. Blood sampling was continued at 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24 days in the prophylactic treatment and at 2, 3, 12, and 24 days in the therapeutic treatment. Six birds were chosen at random from each drug level for the sampling period. The blood concentration of SDM reached a plateau of about 1 ppm after 15 days of feeding with the highest level of about 1.2 ppm attained at 14 days in the prophylactic treatment. In the therapeutic treatment, the level of SDM in the whole blood leveled at 24 hr at approximately 4 ppm, and the highest levels of 30 ppm were attained at 11 days on the drug.

show abstract

Section: Resultssupporting

confidence: 89%

Section: Introductionmentioning

confidence: 99%

Accumulation Rate in the Whole Blood of Market Turkeys Fed Prophylactic and Therapeutic Levels of Sulfadimethoxine

et al. 1986

View full text Add to dashboard Cite

show abstract

“…Council (1980). In a study involving tissue clearance of Rofenaid in chickens and turkeys with arsenicals, Fellig et al (1971) indicated that arsenic was detected only in the liver and kidneys and their levels were both below 1É3 mg kg~1. They also found that arsenic levels were una †ected by the simultaneous feeding with Rofenaid.…”

Section: Introductionmentioning

confidence: 99%

Effects of Roxarsone on Performance, Toxicity, Tissue Accumulation and Residue of Eggs and Excreta in Laying Hens

Chiou

Chen

1997

J. Sci. Food Agric.

View full text Add to dashboard Cite

In this study, we examined the effects of a high dosage of roxarsone in the diet on the performance, liver function, and its residue in liver, eggs and excreta of laying hens. Seventy‐five 32‐week‐old layers were selected and randomly allocated into five dietary treatments with three replications for each treatment. Feeding periods were 4 weeks with an additional week for withdrawal. The experimental diets included 0, 11, 22, 44 or 88 mg kg‐1 arsenic from roxarsone, respectively. Dietary arsenic above 44 mg kg‐1 significantly decreased the egg production and feed intake of the layer (P < 0·05). Layers ceased to produce eggs after two weeks of feeding the 88 mg kg‐1 arsenic supplement diet. Where the enzyme activities in the serum, aspartate aminotransferase (AST), lactate dehydrogenase (LDH), creatine kinase (CK) significantly increased. Also, the liver weight did not only significantly decrease (P < 0·05), but was also damaged on histological examination. Moreover, arsenic residues in the liver, eggs and the excreta significantly increased as dietary arsenic level was increased (P < 0·05). The serum enzyme activities of AST, LDH, CK returns to normal after a week of the drug withdrawal. Arsenic residues in liver, egg and excreta also significantly declined in the withdrawal period (P < 0·05). Furthermore, the hepatic cells were vacuolised from layers treated with 88 mg kg‐1 of arsenic. © 1997 SCI.

show abstract

“…An affinity of this compound for melanin was suggested (Bergsjo et al 1979). Ormetoprim did not persist in the skin of chickens and turkeys (Fellig et al 1972).…”

Section: Resultsmentioning

confidence: 98%

Tissue Distribution and Renal Excretion of Ormetoprim after Intravascular and Oral Administration in the Channel Catfish (Ictalurus punctatus)

Plakas¹,

Dickey²,

Barron³

et al. 1990

Can. J. Fish. Aquat. Sci.

View full text Add to dashboard Cite

1990. Tissue distribution and renal excretion of ormetoprim after intravascular and oral administration in the channel catfish (Ictalurus punctatus). Can. 1. Fish. Aquat. Sci. 47: 766-771.Ormetoprim is used to potentiate sulfadimethoxine in treating certain bacterial diseases of aquatic species. The tissue disposition and renal excretion of ormetoprim and metabolites were examined after intravascular and oral administration (4 mg-kg-') in channel catfish (Ictalurus punctatus). Peak plasma level (0.66 p,g.mL-') of 14C-ormetoprim occurred at 6 h after oral dosing. The oral bioavailability was estimated at 52%. Ormetoprim and metabolites were widely distributed in the tissues. The tissue concentrations were highest in the liver, trunk kidney, head kidney, and spleen. Clearance of the radiolabel from tissues was rapid. The muscle contained 49.3% of the intravascularly administered dose at 2 h; however, at 72 h, less than 1 % of the dose remained in this tissue. 14C-Ormetoprim was more persistent in the skin than in the muscle. Ormetoprim was extensively metabolized in catfish. After intravascular administration, 21 . l % of the dose of 14C-ormetoprim was eliminated in the urine in 48 h, predominantly as polar metabolites; less than 4% of the dose was eliminated as the parent compound. Biliary excretion was a minor route of elimination (5-6% of the dose). The data suggest branchial excretion of ormetoprim and/or metabolites.L'ormetoprim est un activateur de la sulfadimethoxine dans le traitement de certaines infections bactkriennes d'especes aquatiques. Le dep6t dans les tissus et I'excretion renale de I'ormetoprim et de ses metabolites ont 6t6 suivis apr6s I'administration par voie orale ou intravasculaire (4 mg-kg-') A des barbues de rivi6re (Ictalurus punctatus). La concentration maximale dans le plasma (0,66 pg.mL-l) de 14C-ormetoprim a et6 observee 6h apres administration par voie orale. La biodisponibilite du produit administre sous forme orale a 6te kvaluee A 52 %. L'ormetoprim et ses metabolites sont largement distribues dans les tissus. Les concentrations tissulaires le plus devees ont ete observees dans le foie, I'opistonephros, le pronephros et la rate. La clearance tissulaire du produ it radiomarque est rapide. Deux heures apr6s I'admin istration intravasculaire, le tissu musculaire contenait 49,3 % de la dose; apr6s 72 h cependant, ce tissu n'en contenait plus que moins d'un p. cent. Le 14C-ormetoprim s'est revel6 plus persistant dans la peau que dans le tissu musculaire. L'ormetoprim est largement metabolise chez la barbue. Apres I'administration intravasculaire, 21,l % du 14C-ormetoprim est dimin6 dans I'urine au bout de 48 h, principalement sous forme de metabolites polaires. Moins de 4 % de la dose est elimine sous la forme du compose-parent. L'excretion biliaire constitue une voie mineure d'elin-ina at ion (5 A 6 % de la dose administree).Les resultats indiquent qu'il se produit une excretion branchiale de 110rm6toprim ou de ses metabolites.

show abstract

Tissue Clearance of Rofenaid® in Chickens and Turkeys

Cited by 12 publications

References 8 publications

Accumulation Rate in the Whole Blood of Market Turkeys Fed Prophylactic and Therapeutic Levels of Sulfadimethoxine

Accumulation Rate in the Whole Blood of Market Turkeys Fed Prophylactic and Therapeutic Levels of Sulfadimethoxine

Effects of Roxarsone on Performance, Toxicity, Tissue Accumulation and Residue of Eggs and Excreta in Laying Hens

Tissue Distribution and Renal Excretion of Ormetoprim after Intravascular and Oral Administration in the Channel Catfish (Ictalurus punctatus)

Contact Info

Product

Resources

About